Scientific Clinical | Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma
(WorldNews France)

Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma Paris, France and Cambridge, Massachusetts, USA, October 23, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product candidate, NBTXR3, in soft tissue sarcoma. The last patients are expected to start their treatment in two to three weeks. Elsa Borghi, Nanobiotix`s Chief Medical Officer commented: "We are pleased to have reached this important milestone in Nanobiotix`s soft tissue...